Trump White House confirms pricing deal with weight-loss-drug giants Eli Lilly, Novo Nordisk

Core Insights - The Trump administration has confirmed a deal with Eli Lilly and Novo Nordisk to lower prices for their GLP-1 drugs for certain Medicare beneficiaries [1] Company Summary - Eli Lilly and Novo Nordisk are involved in a pricing agreement aimed at making their GLP-1 drugs more affordable for Medicare patients [1]